NEUROTROPE BIOSCIENCE
Neurotrope is a biopharmaceutical and diagnostics company principally focused on developing two product platforms, a diagnostic test for Alzheimer’s Disease and a drug candidate called bryostatin for the treatment of Alzheimer’s Disease, both of which are in the clinical testing stage.
NEUROTROPE BIOSCIENCE
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2012-01-01
Address:
Fort Lauderdale, Florida, United States
Country:
United States
Website Url:
http://www.neurotrope.com
Total Employee:
11+
Status:
Active
Contact:
945-632-6630
Total Funding:
21.9 M USD
Technology used in webpage:
Amazon Google Apps For Business GoDaddy DNS AWS Global Accelerator
Similar Organizations
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
William S. Singer Vice Chairman and Secretary @ Neurotrope Bioscience
Vice Chairman and Secretary
Daniel L. Alkon Chief Scientific Officer and Director @ Neurotrope Bioscience
Chief Scientific Officer and Director
James New Chief Executive Officer and Chairman of the Board @ Neurotrope Bioscience
Chief Executive Officer and Chairman of the Board
Official Site Inspections
http://www.neurotrope.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Neurotrope Bioscience"
Neurotrope Inc. - LinkedIn
We are a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.See details»
IR - Synaptogenix
Newark, NJ, June 24, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its operating wholly-owned subsidiary (“Neurotrope”), will conduct a …See details»
Neurotrope, Inc. Completes Independent Spin-off of …
Dec 8, 2020 · Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., today announced the successful spin-off of substantially all of the legacy assets and liabilities of …See details»
Neurotrope and Metuchen Pharmaceuticals Announce …
May 18, 2020 · NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ — Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held …See details»
Neurotrope completes formation of new company …
Dec 14, 2020 · Neurotrope announced the completion of an independent spin-off of neurotrope bioscience, which has now been renamed as Synaptogenix, trading under the symbol SNPX.See details»
Synaptogenix Company Profile - Craft
Oct 22, 2024 · Synaptogenix (formerly known as Neurotrope Bioscience) is a biopharmaceutical company that specializes in therapies for neurodegenerative diseases. It develops a product …See details»
Neurotrope, Inc. Company Profile | New York, NY
Find company research, competitor information, contact details & financial data for Neurotrope, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
Neurotrope Bioscience Announces Agreement with …
NEW YORK, July 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company") today announced that its wholly-owned subsidiary, Neurotrope Bioscience, …See details»
Neurotrope, Inc. Approves Spin-Off of Neurotrope …
Nov 20, 2020 · Neurotrope is a clinical-stage biopharmaceutical company working to develop novel therapies for neurodegenerative diseases.See details»
Neurotrope, In Consultation With Leading Neuroscientists, …
NEW YORK, May 7, 2018 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, …See details»
Neurotrope completes spin-off of biopharmaceutical unit
Dec 10, 2020 · The spin-off is part of Neurotrope's planned merger with privately held Metuchen Pharmaceuticals LLC forming Petros Pharmaceuticals Inc. Neurotrope Bioscience's assets …See details»
Neurotrope Nears Breakthrough In New Alzheimer's …
Neurotrope's near-term market moving catalyst is top-line efficacy data which is due towards the end of April. Positive Phase IIb results would entirely transform the way Alzheimer's is treated...See details»
BryoLogyx Announces Agreements with Neurotrope to …
Jun 10, 2020 · Under the first agreement, Neurotrope will transfer to BryoLogyx the right to develop bryostatin‑1 for the potential treatment of CD22+ B-cell acute lymphoblastic leukemia …See details»
Neurotrope Launches Long-term Trial of Bryostatin-1
Jun 15, 2020 · Neurotrope has announced the launch of a Phase 2 clinical trial to investigate the long-term use of bryostatin-1 for moderate and moderately severe Alzheimer’s disease. The …See details»
Synaptogenix | Neurotrope Announces Top-line Results …
NEW YORK, Sept. 9, 2019 /PRNewswire/ — Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, …See details»
Neurotrope Provides Corporate Update After Completing …
NEW YORK, Jan. 22, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for...See details»
Neurotrope: Lessons Learned (NASDAQ:NTRP-DEFUNCT …
May 4, 2017 · Neuronal cell death can be limited by NMDA receptor antagonists and antioxidants. The likely key to treating Alzheimer's disease is to inhibit NMDA receptor activation, inhibit …See details»
Neurotrope: A Shameful PR Stunt - Science | AAAS
May 3, 2017 · Neurotrope, on two standardized tests blessed by leading AD organizations, delivered figures even lower, meaning greater probability of results not being accidental. This …See details»
What are neurotropic vitamins & why do we need them?
Apr 22, 2016 · Neurotropic vitamins, says medicatione.com, usually combine variants of Vitamin B (i.e. Vitamin B Complex). They mainly consist of B1 (Thiamine), B2 (Riboflavin), B6 …See details»
Neurotrope Launches New Long-Term Clinical Trial of …
NEW YORK, May 28, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with …See details»